<DOC>
	<DOCNO>NCT00086294</DOCNO>
	<brief_summary>This study evaluate effect experimental drug call ACP-103 Parkinson 's disease symptom dyskinesias ( involuntary movement ) develop result long-term levodopa treatment . ACP-103 change spread certain brain signal affect patient Parkinson 's disease . Patients relatively advance Parkinson 's disease dyskinesias 30 80 year age may eligible study . Candidates screen complete medical history physical examination , neurological evaluation , blood urine test , electrocardiogram ( ECG ) . A brain magnetic resonance imaging ( MRI ) scan , CT scan , chest x-ray may do medically indicate . Patients enrol study , possible , stop take antiparkinsonian medication one month ( 2 month Selegiline ) study begin throughout duration . Exceptions Sinemet ( levodopa/carbidopa ) , Mirapex ( pramipexole ) Requip ( ropinirole ) . Levodopa Dose Finding After screen evaluation , patient admit NIH Clinical Center 2 3 day undergo levodopa `` dose-finding '' procedure . For test , patient stop take Sinemet instead levodopa infused vein . During infusion , drug dose increase slowly either 1 ) parkinsonian symptom improve , 2 ) unacceptable side effect occur , 3 ) maximum study dose reach . Side effect monitor closely infusion , parkinsonian symptom evaluate frequently infusion . The infusion usually begin early morning continue even . Once infusion finish , patient resume take regular oral Sinemet dose . The infusion repeat week 1-day inpatient evaluation . Treatment Patients randomly assign take either ACP-103 follow placebo ( look-alike pill active ingredient ) week 10 week vice versa ( placebo follow ACP-103 ) . Patients admit Clinical Center dose . During admission brief medical examination , blood urine test , ECG , review symptom change condition . They also infusion levodopa ( see ) previously determine optimal rate . Parkinsonism symptom dyskinesias evaluate every 30 minute 6 hour . At end infusion rating , patient discharge home regular Parkinson 's medication follow visit . Two week final dose ACP-103 placebo , patient contact telephone follow-up safety check . At time , investigator may ask patient return clinic close evaluation .</brief_summary>
	<brief_title>ACP-103 Treat Parkinson 's Disease</brief_title>
	<detailed_description>Introduction : In Parkinson 's disease ( PD ) , levodopa-induced dyskinesia motor fluctuation frequent , disable complication . Therefore , imperative find nondopaminergic approach palliation parkinsonian sign . Previously , demonstrate drug block 5HT2A receptor benefit motor dysfunction parkinsonian animal . Objective : To test hypothesis blockade serotonin 2A/2C receptor ( 5HT2A/C ) lessen severity parkinsonian sign levodopa-associated motor response complication PD patient . Methods : In placebo-controlled , proof-of-principle study , effect 5HT2A/C receptor inverse agonist ACP-103 levodopa induce motor complication parkinsonian sign assess 20 patient moderately advance Parkinson 's disease . Efficacy assess use validate motor function scale . Safety monitor mean frequent clinical evaluation laboratory test . Risks benefit : Risks involve study minor increase minimal risk deem reasonable relation potential benefit . This investigation lead good understand pathophysiology treatment levodopa-induced motor complication PD .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Pimavanserin</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients meet follow inclusion criterion eligible participate study : 1 . Patient age 30 80 ( inclusive ) ; 2 . Patient diagnose idiopathic Parkinson 's disease base presence characteristic clinical history neurological finding ; 3 . Patient relatively advance disease levodopaassociated motor response complication , include peakdose dyskinesia wearingoff fluctuation ; 4 . Patient willing adhere protocol requirement evidence write , informed consent . EXCLUSION CRITERIA : Patients meet follow exclusion criterion enrol immediately exclude study , appropriate : 1 . Patient history medical condition reasonably expect subject patient unwarranted risk , include bronchospasm lung disease , renal hepatic disease , clinically significant cardiac arrhythmia and/or myocardial ischemia ; 2 . Patients clinically significant orthostatic hypotension ; 3 . Patient clinically significant laboratory abnormality include renal hepatic function elevation great twice upper limit normal ; 4 . Patient unable treat levodopa/carbidopa alone single , relatively shortacting dopamine agonist , pramipexole ropinirole ; 5 . Patient take prohibit concomitant medication list : The following medication forbid least one month prior randomization course study : Anticoagulants : etomidate , erythromycin , oral azole antifungal , cyclosporine , cisapride , astemizole ; NMDA antagonists : e.g . amantadine , budipine , memantine , remacemide , dextromethorphan ; Any investigational drug ; Drugs use primarily treat Parkinson 's disease may modify parkinsonian symptom : neuroleptic , metoclopramide , compazine , beta blocker ; Drugs significant muscarinic receptor antagonist activity : Cogentin , Akineton , Artane , Ditropan , Detrol , Elavil , Anafranil , Norpramine , Sinequan , Tofranil , Pamelor ; Drugs know improve dyskinesia : amantadine , dextromethorphan , betablockers , fluoxitene , clozapine , quetiapine , olanzapine , buspirone , anxiolytic , antipsychotic , cannabinoid receptor antagonist , adenosine A2a antagonist ; Drugs know exacerbate dyskinesia : sodium valproate , CNS stimulant ; Drugs know 5HT receptor affinity : ritanserin , sumatriptan Drugs know interact serotonergic mechanism exclude 5HT3 receptor base antiemetic ; Dopamine agonists know relatively long halflife : cabergoline pergolide . 6 . Patient use unwilling continue use adequate contraceptive method ( oral contraception , surgical sterilization , IUD , diaphragm conjunction spermicidal foam condom male partner , systemic contraception ) last 30 day , least one year postmenopausal ( female ) ; 7 . Patient pregnant breastfeeding ; 8 . Patient prior bilateral pallidotomy ablative surgery treatment PD ; 9 . Patient cognitive impairment ( MMSE less 24 ) ; 10 . Patient participate clinical study investigational drug within last 30 day ; 11 . Patient condition ( active drug alcohol abuse ) , opinion investigator , would interfere compliance safety ; 12 . Patient unwilling sign inform consent comply protocol requirement . 13 . Any previous exposure ACP103</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 15, 2007</verification_date>
	<keyword>Non-Dopaminergic</keyword>
	<keyword>Dyskinesias</keyword>
	<keyword>Fluctuations</keyword>
	<keyword>Inverse Agonist</keyword>
	<keyword>ACP-103</keyword>
	<keyword>Parkinson Disease</keyword>
	<keyword>PD</keyword>
</DOC>